About Us Services Careers FAQ Contact Us 0
Home Medical Devices Biopharmaceutical Contract Manufacturing Market Outlook, Share to 2031
Biopharmaceutical Contract Manufacturing Market

Biopharmaceutical Contract Manufacturing Market Size, Share & Trends Analysis Report By Product (Finished Dosage Form, Active Pharmaceutical Ingredients (APIs)), By Biologics (Monoclonal Antibodies (mAbs), Vaccines, Others), By Expression System (Mammalian, Non-Mammalian), By Scale of Operation (Commercial, Research (Clinical and Preclinical)), By Company Size (Large and Very Large Companies, Small and Mid-sized Companies) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2023-2031

Report Code: SRMD3658DR
Last Updated : March 20, 2023
Author : Straits Research
Starting From
USD 2300
Buy Now
File Formats

Table Of Content

  1. Executive Summary
    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
    1. Drivers
    2. Market Warning Factors
    3. Latest Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
    1. North America
    2. Europe
    3. APAC
    4. Middle East and Africa
    5. LATAM
  2. ESG Trends
    1. Global Biopharmaceutical Contract Manufacturing Market Introduction
    2. By Product
      1. Introduction
        1. Product By Value
      2. Finished Dosage Form
        1. By Value
      3. Active Pharmaceutical Ingredients (APIs)
        1. By Value
    3. By Biologics
      1. Introduction
        1. Biologics By Value
      2. Monoclonal Antibodies (mAbs)
        1. By Value
      3. Vaccines
        1. By Value
      4. Others
        1. By Value
    4. By Expression System
      1. Introduction
        1. Expression System By Value
      2. Mammalian
        1. By Value
      3. Non-Mammalian
        1. By Value
    5. By Scale of Operation
      1. Introduction
        1. Scale of Operation By Value
      2. Commercial
        1. By Value
      3. Research (Clinical and Preclinical)
        1. By Value
    6. By Company Size
      1. Introduction
        1. Company Size By Value
      2. Large and Very Large Companies
        1. By Value
      3. Small and Mid-sized Companies
        1. By Value
    1. Introduction
    2. By Product
      1. Introduction
        1. Product By Value
      2. Finished Dosage Form
        1. By Value
      3. Active Pharmaceutical Ingredients (APIs)
        1. By Value
    3. By Biologics
      1. Introduction
        1. Biologics By Value
      2. Monoclonal Antibodies (mAbs)
        1. By Value
      3. Vaccines
        1. By Value
      4. Others
        1. By Value
    4. By Expression System
      1. Introduction
        1. Expression System By Value
      2. Mammalian
        1. By Value
      3. Non-Mammalian
        1. By Value
    5. By Scale of Operation
      1. Introduction
        1. Scale of Operation By Value
      2. Commercial
        1. By Value
      3. Research (Clinical and Preclinical)
        1. By Value
    6. By Company Size
      1. Introduction
        1. Company Size By Value
      2. Large and Very Large Companies
        1. By Value
      3. Small and Mid-sized Companies
        1. By Value
    7. U.S.
      1. By Product
        1. Introduction
          1. Product By Value
        2. Finished Dosage Form
          1. By Value
        3. Active Pharmaceutical Ingredients (APIs)
          1. By Value
      2. By Biologics
        1. Introduction
          1. Biologics By Value
        2. Monoclonal Antibodies (mAbs)
          1. By Value
        3. Vaccines
          1. By Value
        4. Others
          1. By Value
      3. By Expression System
        1. Introduction
          1. Expression System By Value
        2. Mammalian
          1. By Value
        3. Non-Mammalian
          1. By Value
      4. By Scale of Operation
        1. Introduction
          1. Scale of Operation By Value
        2. Commercial
          1. By Value
        3. Research (Clinical and Preclinical)
          1. By Value
      5. By Company Size
        1. Introduction
          1. Company Size By Value
        2. Large and Very Large Companies
          1. By Value
        3. Small and Mid-sized Companies
          1. By Value
    8. Canada
    1. Introduction
    2. By Product
      1. Introduction
        1. Product By Value
      2. Finished Dosage Form
        1. By Value
      3. Active Pharmaceutical Ingredients (APIs)
        1. By Value
    3. By Biologics
      1. Introduction
        1. Biologics By Value
      2. Monoclonal Antibodies (mAbs)
        1. By Value
      3. Vaccines
        1. By Value
      4. Others
        1. By Value
    4. By Expression System
      1. Introduction
        1. Expression System By Value
      2. Mammalian
        1. By Value
      3. Non-Mammalian
        1. By Value
    5. By Scale of Operation
      1. Introduction
        1. Scale of Operation By Value
      2. Commercial
        1. By Value
      3. Research (Clinical and Preclinical)
        1. By Value
    6. By Company Size
      1. Introduction
        1. Company Size By Value
      2. Large and Very Large Companies
        1. By Value
      3. Small and Mid-sized Companies
        1. By Value
    7. U.K.
      1. By Product
        1. Introduction
          1. Product By Value
        2. Finished Dosage Form
          1. By Value
        3. Active Pharmaceutical Ingredients (APIs)
          1. By Value
      2. By Biologics
        1. Introduction
          1. Biologics By Value
        2. Monoclonal Antibodies (mAbs)
          1. By Value
        3. Vaccines
          1. By Value
        4. Others
          1. By Value
      3. By Expression System
        1. Introduction
          1. Expression System By Value
        2. Mammalian
          1. By Value
        3. Non-Mammalian
          1. By Value
      4. By Scale of Operation
        1. Introduction
          1. Scale of Operation By Value
        2. Commercial
          1. By Value
        3. Research (Clinical and Preclinical)
          1. By Value
      5. By Company Size
        1. Introduction
          1. Company Size By Value
        2. Large and Very Large Companies
          1. By Value
        3. Small and Mid-sized Companies
          1. By Value
    8. Germany
    9. France
    10. Spain
    11. Italy
    12. Russia
    13. Nordic
    14. Benelux
    15. Rest of Europe
    1. Introduction
    2. By Product
      1. Introduction
        1. Product By Value
      2. Finished Dosage Form
        1. By Value
      3. Active Pharmaceutical Ingredients (APIs)
        1. By Value
    3. By Biologics
      1. Introduction
        1. Biologics By Value
      2. Monoclonal Antibodies (mAbs)
        1. By Value
      3. Vaccines
        1. By Value
      4. Others
        1. By Value
    4. By Expression System
      1. Introduction
        1. Expression System By Value
      2. Mammalian
        1. By Value
      3. Non-Mammalian
        1. By Value
    5. By Scale of Operation
      1. Introduction
        1. Scale of Operation By Value
      2. Commercial
        1. By Value
      3. Research (Clinical and Preclinical)
        1. By Value
    6. By Company Size
      1. Introduction
        1. Company Size By Value
      2. Large and Very Large Companies
        1. By Value
      3. Small and Mid-sized Companies
        1. By Value
    7. China
      1. By Product
        1. Introduction
          1. Product By Value
        2. Finished Dosage Form
          1. By Value
        3. Active Pharmaceutical Ingredients (APIs)
          1. By Value
      2. By Biologics
        1. Introduction
          1. Biologics By Value
        2. Monoclonal Antibodies (mAbs)
          1. By Value
        3. Vaccines
          1. By Value
        4. Others
          1. By Value
      3. By Expression System
        1. Introduction
          1. Expression System By Value
        2. Mammalian
          1. By Value
        3. Non-Mammalian
          1. By Value
      4. By Scale of Operation
        1. Introduction
          1. Scale of Operation By Value
        2. Commercial
          1. By Value
        3. Research (Clinical and Preclinical)
          1. By Value
      5. By Company Size
        1. Introduction
          1. Company Size By Value
        2. Large and Very Large Companies
          1. By Value
        3. Small and Mid-sized Companies
          1. By Value
    8. Korea
    9. Japan
    10. India
    11. Australia
    12. Taiwan
    13. South East Asia
    14. Rest of Asia-Pacific
    1. Introduction
    2. By Product
      1. Introduction
        1. Product By Value
      2. Finished Dosage Form
        1. By Value
      3. Active Pharmaceutical Ingredients (APIs)
        1. By Value
    3. By Biologics
      1. Introduction
        1. Biologics By Value
      2. Monoclonal Antibodies (mAbs)
        1. By Value
      3. Vaccines
        1. By Value
      4. Others
        1. By Value
    4. By Expression System
      1. Introduction
        1. Expression System By Value
      2. Mammalian
        1. By Value
      3. Non-Mammalian
        1. By Value
    5. By Scale of Operation
      1. Introduction
        1. Scale of Operation By Value
      2. Commercial
        1. By Value
      3. Research (Clinical and Preclinical)
        1. By Value
    6. By Company Size
      1. Introduction
        1. Company Size By Value
      2. Large and Very Large Companies
        1. By Value
      3. Small and Mid-sized Companies
        1. By Value
    7. UAE
      1. By Product
        1. Introduction
          1. Product By Value
        2. Finished Dosage Form
          1. By Value
        3. Active Pharmaceutical Ingredients (APIs)
          1. By Value
      2. By Biologics
        1. Introduction
          1. Biologics By Value
        2. Monoclonal Antibodies (mAbs)
          1. By Value
        3. Vaccines
          1. By Value
        4. Others
          1. By Value
      3. By Expression System
        1. Introduction
          1. Expression System By Value
        2. Mammalian
          1. By Value
        3. Non-Mammalian
          1. By Value
      4. By Scale of Operation
        1. Introduction
          1. Scale of Operation By Value
        2. Commercial
          1. By Value
        3. Research (Clinical and Preclinical)
          1. By Value
      5. By Company Size
        1. Introduction
          1. Company Size By Value
        2. Large and Very Large Companies
          1. By Value
        3. Small and Mid-sized Companies
          1. By Value
    8. Turkey
    9. Saudi Arabia
    10. South Africa
    11. Egypt
    12. Nigeria
    13. Rest of MEA
    1. Introduction
    2. By Product
      1. Introduction
        1. Product By Value
      2. Finished Dosage Form
        1. By Value
      3. Active Pharmaceutical Ingredients (APIs)
        1. By Value
    3. By Biologics
      1. Introduction
        1. Biologics By Value
      2. Monoclonal Antibodies (mAbs)
        1. By Value
      3. Vaccines
        1. By Value
      4. Others
        1. By Value
    4. By Expression System
      1. Introduction
        1. Expression System By Value
      2. Mammalian
        1. By Value
      3. Non-Mammalian
        1. By Value
    5. By Scale of Operation
      1. Introduction
        1. Scale of Operation By Value
      2. Commercial
        1. By Value
      3. Research (Clinical and Preclinical)
        1. By Value
    6. By Company Size
      1. Introduction
        1. Company Size By Value
      2. Large and Very Large Companies
        1. By Value
      3. Small and Mid-sized Companies
        1. By Value
    7. Brazil
      1. By Product
        1. Introduction
          1. Product By Value
        2. Finished Dosage Form
          1. By Value
        3. Active Pharmaceutical Ingredients (APIs)
          1. By Value
      2. By Biologics
        1. Introduction
          1. Biologics By Value
        2. Monoclonal Antibodies (mAbs)
          1. By Value
        3. Vaccines
          1. By Value
        4. Others
          1. By Value
      3. By Expression System
        1. Introduction
          1. Expression System By Value
        2. Mammalian
          1. By Value
        3. Non-Mammalian
          1. By Value
      4. By Scale of Operation
        1. Introduction
          1. Scale of Operation By Value
        2. Commercial
          1. By Value
        3. Research (Clinical and Preclinical)
          1. By Value
      5. By Company Size
        1. Introduction
          1. Company Size By Value
        2. Large and Very Large Companies
          1. By Value
        3. Small and Mid-sized Companies
          1. By Value
    8. Mexico
    9. Argentina
    10. Chile
    11. Colombia
    12. Rest of LATAM
    1. Biopharmaceutical Contract Manufacturing Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    1. Merck KGAA
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. AGC Biologics
    3. Catalent
    4. FUJIFILM
    5. Patheon
    6. Piramal Pharma Solutions
    7. Pfizer
    8. Serum Institute of India
    9. WuXi Biologics
    10. Samsung BioLogics
    11. Thermo Fisher Scientific Inc.
    12. AbbVie Inc.
    13. Emergent BioSolutions
    14. Biocon
    15. BioCina
    16. Ajinomoto
    17. Albany Molecular Research Inc.
    18. Asymchem
    19. Cobra Biologics
    20. Charles River Laboratories
    21. Goodwin Biotechnology
    22. KBI Biopharma
    1. Research Data
      1. Secondary Data
        1. Major secondary sources
        2. Key data from secondary sources
      2. Primary Data
        1. Key data from primary sources
        2. Breakdown of primaries
      3. Secondary And Primary Research
        1. Key industry insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  3. Disclaimer

Related Reports

Global Report
Biopharmaceutical CMO And CRO Market Insights The global biopharmaceutical CMO And CRO market size was valued at USD 28.70 billion in 2021 and is projected to reach USD 51.36 billion by 2030, growing at a CAGR of 6.68% from 2022 to 2030.
Buy Now
Global Report
Medical Component Manufacturing Market Size & Trends The global medical component manufacturing market size was valued at USD 15.34 billion in 2023. It is expected to reach USD 24.03 billion in 2032, growing at a CAGR of 5.1% over the forec
Buy Now
Global Report
Market OverviewThe global personal care contract manufacturing market size was valued at USD 22.24 billion in 2023. It is expected to reach USD 39.93 billion in 2032, growing at a CAGR of 7.80% over the forecast period (2024-32). Personal care brands
Buy Now
Global Report
The global pharmaceutical contract packaging market size was valued at USD 13.02 billion in 2021. It is projected to reach USD 31.21 billion by 2030, growing at a CAGR of 10.2% during the forecast period (2022-2030). Drugs must be packaged safely af
Buy Now

Purchase Benefits

  • Eligible for a free updated report next year
  • Completely customizable scope
  • 30% discount on your next purchase
  • Dedicated account manager
  • Query resolution within 24 hours
  • Permission to print the report

We are featured on :

www.straitsresearch.com
© Copyright 2025. All rights Reserved.